Marketresearchnews

Friday, 21 May 2021

Impact of Existing and Emerging Global Spirometry Market Trends And Forecast 2020-2027

The global spirometry market forecast 2027 predicted to exhibit a 10.03% CAGR in forecast period to reach USD 1,106.76 million by 2027, as per the latest report by Market Research Future (MRFR). This can be attributed to the sharp rise in the cases of chronic obstructive pulmonary disorders (COPD) and asthma.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6539

Spirometry is a basic test conducted by clinicians to evaluate the status of lungs. It is vital for diagnosing asthma, COPD, and other breathing disorders. The tests are carried out with the help of spirometers. Factors such as the increasing elderly populace, constrained budgets of healthcare institutes, and technological advances of respiratory care devices can drive the market demand over the forecast period. Initiatives taken by governments to curb smoking, home utilization spirometers, and focus on monitoring respiratory diseases can further the spirometry market till 2023.

Report Overview

The report provides an accurate overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global spirometry market segmented on the basis of product, technology, application, end-user, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.

Spirometry Market Segment Overview

The global market is segmented by product, technology, application, and end-user. Various products in the market include table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. Based on technology, the market is segmented into volume measurement spirometry, peak flow meters (PFM), and flow measurement spirometry.

By application, the spirometry market is segmented into diagnostic and treatment monitoring. The former is further segmented into COPD, asthma, and interstitial pulmonary fibrosis. End-users in the market include research & academic institutes, diagnostic centers, hospitals & clinics, and home care.

The segments covered in the spirometry market report are analyzed with respect to four main regions – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA), with respective country-level market sizing. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market ladder.

Spirometry Market – Competitive Landscape

Prominent players in the spirometry market include Carefusion Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Nihon Kohden Corporation (Germany), MGC Diagnostics Corporation (U.S.), Vitalograph (U.K.), Schiller AG (Switzerland), COSMED srl (Italy), Hill-Rom Holdings, Inc. (U.S.), Midmark Corporation (U.S.), Smiths Medical Inc. (U.S.), and Koninklijke Philips N.V. (The Netherlands).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Surgical Stapler Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Market Scenario

The Global Surgical Stapler Market analysis expected to grow during the forecast period (2018 to 2023) at a CAGR approx. 7.2 %.

A surgical stapler is a complex mechanical medical device that has been present in the market for years and is mature in technology. Surgical staplers are used in various surgeries such as gastrointestinal, gynecologic, thoracic, and many other surgeries to remove the part of organ and tissues. This surgical stapler reduces the time of surgical procedure. The global surgical stapler market is increasing due to increasing surgical procedures, the introduction of technologically advanced surgical staplers, and growing number of bariatric and other weight loss surgeries. However, due to increasing aesthetic surgeries, breast surgeries, surgical technology, and pediatric surgical procedures, the surgical stapler market size is expected to grow in the future.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6382

However, the high cost of treatment, misuse of funding, and lack of awareness are some of the factors which are expected to hamper the growth of the market during the forecast period.

Segmentation

The global surgical stapler market is segmented into types, product, application, and end-users. Based on types the surgical stapler market is segmented into disposable surgical staplers and reusable surgical staplers. On the basis of the product, the market is segmented into manual surgical staplers and powered surgical staplers. Based on application, the surgical stapler market is segmented into abdominal and pelvic surgery, general surgery, cardiac and thoracic surgery, orthopedic surgery, and other surgical applications. Based on end-user the market is segmented into hospitals, ambulatory surgical centers (ASCs), and clinics.

Regional Market Summary

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The global surgical stapler market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European global surgical stapler market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The global surgical stapler market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The surgical stapler market in the Middle East and Africa has been segmented into the Middle East and Africa.

North America will dominate the surgical stapler market during the forecast period. Technological advancements, growing geriatric population, and rising number of surgical procedures are likely to drive the surgical stapler market during the forecast period. North America and Europe are expected to hold a major share of around 70% of the surgical stapler market during the forecast period. The European market is expected to be the second-largest market. The market growth in this region can be attributed to the increasing awareness and adoption of the advanced surgical technology. Asia-Pacific is expected to be the fastest-growing surgical stapler market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition to the global surgical stapler market by producing cost-effective treatments that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global surgical stapler market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global surgical stapler market are Ethicon. US, LLC., Cardica Inc, Smith and Nephew Plc, CONMED Corporation, Purple Surgical Inc., Welfare Medical Ltd, Reach Surgical, Grena Ltd, B.Braun Melsungen AG, Frankenman International Limited, Zimmer Biomet, Stryker, Meril Life Sciences Pvt. Ltd., Touchstone International Medical Science Co.Ltd, and Medtronic.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/surgical-stapler-market-6382

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Thursday, 20 May 2021

Companion Diagnostics for Oncology Market : The report gives immense knowledge on the competitive nature of key players 2027

Global Companion Diagnostics for Oncology Market was valued at USD 1,603.16 Million in 2019 and is expected to register a CAGR of 22.57% during the forecast period of 2020 to 2027.

Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area. The growing prevalence of cancer across the globe is increasing the preference for targeted therapy, which is affecting the demand for CDx tests. According to Cancer Research UK, there were 17 million new cases of cancer across the world in 2018, in which lung and breast cancer accounted for the largest Companion Diagnostics for Oncology Market share , followed by colorectal and prostate cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10422

Market Dynamics

The key factors driving the market growth are increasing R&D and drug-diagnostic co-development, growing preference for personalized medicine, increasing global incidence of cancer, and increasing product approvals by major players. However, the lack of reimbursement in developing regions may hamper the market growth. The entry of market players in evolving economies creates an opportunity to drive the companion diagnostics for oncology market.

Major market players are focusing on various growth strategies such as product launches, product advancements, and business expansions to cater to the growing need for personalized medicine. These product launches and business expansion drive the growth of the companion diagnostics for oncology market. For instance, in March 2020, Thermo Fisher signed a strategic agreement with Janssen Services to co-develop a companion diagnostic product related to oncology, which will support clinical trial enrollment globally. In March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Similarly, in March 2019, Roche received the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the treatment with Tecentriq in combination with Abraxane. Furthermore, in April 2018, Illumina entered a collaboration with Bristol Myers Squibb Company to utilize Illumina’s next-generation sequencing technology to develop and globally commercialize companion diagnostics for Bristol-Myers Squibb Company’s oncology immunotherapies, and the growing prevalence of cancer across the globe is increasing the preference for targeted therapy which is affecting the demand for CDx tests.

Segmentation

Global Companion Diagnostics for Oncology Market has been divided based on Products & Services, Technology, Indication, and End User.

Global Companion Diagnostics for Oncology Market, on the basis of product & service, has been segmented into assays, kits & reagents and software & services. The assays, kits, & reagents segment is expected to be the largest of 62.1% in 2019 and is projected to be the fastest market owing to their continuous requirement by end users.

Based on technology, the global companion diagnostics for oncology market is segmented into polymerase chain reaction (PCR) and next-generation sequencing (NGS). By technology, polymerase chain reaction (PCR) held a larger market share of 53.8% in 2019, whereas the NGS segment accounted for a CAGR of 25.05% during the forecast period of 2020 to 2027.

The global companion diagnostics for oncology market, on the basis of indication, has been segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. The breast cancer segment accounted for the largest market share in 2019, owing to the huge population suffering from cancer across the globe.

The global companion diagnostics for oncology market, on the basis of end user, is segmented into pharmaceutical & biopharmaceutical companies, laboratories, contract research organizations, and others. The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of 38.2% in 2019, owing to the rising adoption of companion diagnostics for oncology techniques among researchers and clinicians.

Regional Analysis

Global Companion Diagnostics for Oncology Market based on region is segmented into four main regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas accounted for the major share in 2019, whereas Asia-Pacific is projected to be the fastest-growing region during the forecast period.

In the global companion diagnostics for oncology market, the Americas held the largest share of 37.3% in 2019. The market growth in the Americas is due to the high prevalence rate of cancer and other chronic disorders and rising healthcare expenditure. According, to the National Institutes of Health, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Additionally, the American Cancer Society estimated that 1.8 million new cancer cases would be diagnosed in 2020 in the US.

Europe acquired the second-largest market share in 2019. The market is expected to register a sturdy growth rate during the forecast period due to the presence of a large number of companies, growing research and development activities to develop targeted drug therapy for a cancer patient, and rising per capita income increases the preference for personalized medicine. According to the European Journal of Cancer, there were around 3.9 million new cases and 1.9 million deaths from cancer in Europe in 2018. The increasing cancer population supports market growth in this region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period. The rapid growth of the Asia-Pacific regional market is due to the rising number of cancer patients and the growing presence of market players. According to the Global Cancer Observatory, around 1,157,294 cases of cancer were reported in India in 2018. Additionally, growing research funding, rising investments by pharmaceutical and biotechnology companies and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the Asia-Pacific market.

The Middle East & Africa accounted for the least value of USD 82.64 million in 2019. The companion diagnostics for oncology market in countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising drug discovery, and increasing preference for personalized medicines. Also, the growing number of hospitals and research laboratories and increasing investment by healthcare companies in this region drives the growth of the market in Middle East & Africa.

Key Players

The Prominent Players in the Global Companion Diagnostics for Oncology Market are Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, BioMérieux SA, Foundation Medicine, Archer Dx, Qiagen, Thermo Fisher Scientific Inc., Amoy Dx, and Abbott.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Cardiopulmonary Resuscitation Market Industry Production and Demand, Competition News and Trends Forecasts to 2027

Global Cardiopulmonary Resuscitation Market was valued at USD 1,603.16 Million in 2019 and is expected to register a CAGR of 10.50% during the forecast period of 2020 to 2027.

Cardiopulmonary resuscitation (CPR) is a lifesaving technique useful in many emergencies, including a heart attack or near drowning, in which someone's breathing or heartbeat has stopped. During a cardiac arrest, due to an insufficient supply of blood, the heart stops beating. In such conditions, blood circulation vital to sustaining life can be provided by constantly compressing the heart through a physical force applied to the patient’s chest. This rescue technique is termed cardiopulmonary resuscitation (CPR), which is employed in emergencies or conditions to protect the patient from fatal myocardial infarction or brain damage.

Global Cardiopulmonary Resuscitation Market is mainly driven by the increasing prevalence of heart and respiratory diseases, rising geriatric population, rise in government initiatives, increasing global incidence of cancer, and growing product approvals by major players. People worldwide are living longer. According to the World Health Organization, by 2050, the world’s population aged 60 years and older is expected to be 2 billion, up from 900 million in 2015. By 2050, there will be almost this many (120 million) living in China alone, and 434 million people in this age group worldwide. By 2050, 80% of all older people will live in low- and middle-income countries.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1348

Market Dynamics

Heart disease is the leading cause of death in men and women globally. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. It further stated that in 2017, emergency medical services-assessed out-of-hospital cardiac arrest occurred in an estimated 356,461 Americans; emergency medical services treatment was initiated in 52%. The initial recorded cardiac rhythm was ventricular fibrillation, ventricular tachycardia, or shockable by an automated external defibrillator in only 18.7%. Adult survival to hospital discharge was 10.4%; 8.4% had good functional status at discharge. Furthermore, according to NHS England, the respiratory disease affects one in five people and is the third-biggest cause of death in England (after cancer and cardiovascular disease). According to a new Tulane University study published in The Lancet, chronic obstructive pulmonary disease (COPD) is widespread in China, with 8.6% of the country's adult population with almost 100 million people suffering from chronic lung disease. In addition, as per the World Health Organization, it is estimated that 54% of deaths from noncommunicable diseases in the Eastern Mediterranean Region are due to cardiovascular diseases. Deaths attributed to cardiovascular diseases (of total deaths) range from 49% in Oman to 13% in Somalia. The prevalence of cardiovascular diseases is due to sedentary lifestyles and common risk factors, such as hypertension (ranging from 28% in the UAE to 41% in Libya and Morocco); diabetes (ranging from 4% in the Islamic Republic of Iran to 19% in Sudan) and hypercholesterolemia (ranging from 14% in Lebanon to 52% in the Islamic Republic of Iran). Effective CPR can improve the survival rate of patients with cardiac and respiratory diseases. Application of CPR immediately can increase the survival rate of victims significantly. A study by the American Heart Association states that 70% of Americans feel helpless in cardiac emergencies as they are not aware of administering CPR.

The International Liaison Committee on Resuscitation (ILCOR) launched the first global “World Restart a Heart (WRAH)” initiative in 2018. The aim was to increase public awareness and improve the rates of bystander cardiopulmonary resuscitation (CPR) for victims of cardiac arrest.

Segmentation

Global Cardiopulmonary Resuscitation Market has been divided based on Product Type, Compressor Type, Application, and End User.

On the basis of Product Type, the market is bifurcated into piston CPR devices, load-distributing band (LDB), active compression-decompression (ACD) devices and impedance threshold device, extracorporeal techniques and invasive perfusion devices, and others. The piston CPR devices segment is expected to register the highest CAGR of 11.57% during the forecast period.

On the basis of compressor type, the market is bifurcated into manual CPR and automatic mechanical CPR. The automatic mechanical CPR segment accounted for a larger Cardiopulmonary Resuscitation market share with a value of USD 101.6 million in 2019.

On the basis of application, the market is bifurcated into emergency departments, coronary & intensive care units, organ transplant facilities, air medevac units, and EMT rescue units. The EMT rescue units segment is expected to register the highest CAGR of 12.71% during the forecast period owing to the rise in the availability of a skilled workforce across the globe.

On the basis of end user, the market is bifurcated into hospitals and clinics, cardiac catheterization laboratories, organ transplant units, and others. The hospitals and clinics segment accounted for the largest market share at a value of USD 136.1 million in 2027. This large share can be attributed to the growing awareness of many cardiovascular disease and arrhythmia.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cardiopulmonary-resuscitation-market-1348

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Primary Cells Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

Human Primary Cells Market is expected to register a CAGR of 8.13% to reach USD 1,233.67 Million till 2025.

Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical method. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.

Key factors that drive the primary cells market are the rapid growth in the biotechnology and biopharmaceutical industries, growing cancer research, rising adoption of primary cells over cell lines, increasing demand for monoclonal antibodies, and increasing healthcare expenditure are anticipated to drive the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6296

However, factors such as the high cost of advanced primary cells, and the risk of contamination may hamper the growth of the market. The increasing preference of primary cells in research and development to develop new drug acts as opportunities for the growth of the primary cells market.

Market Dynamics

Growing cancer research across the world demand. Cancer is one of the major causes of death across the globe and is responsible for a large number of deaths. Different pharmaceutical companies and research institutes are involved in developing cancer treatment drugs using cell culture. The increasing prevalence of cancer across the globe is promoting the demand for research activities to develop new drugs. According to the National Cancer Institute in 2018, around 1,735,350 cases of cancer were diagnosed in the US alone.

Additionally, Cancer Research UK reported that in 2018 the new cases of cancer were reported to be 17 million across the world. The increasing number of populations suffering from cancer increases the demand for new research activities to develop new drugs, which ultimately increases the demand for products such as primary cell culture. For instance, the National Cancer Institute conducts different research on cancer biology, cancer genomics, and causes of cancer using primary cell culture. Additionally, there are different major and small manufacturers and suppliers, such as Merck KGaA and PromoCell GmbH, who provide primary cells for cancer research.

Segmentation

The Global Primary Cells Market is segmented into source, Type, and End User. By source, the market has been segmented into hematopoietic cells, skin cells, gastrointestinal cells, liver cells, lung cells, and skeletal and muscle cells.

Based on type, the market has been segmented into human primary cells and animal primary cells. On the basis of end user, the market has been segmented into pharmaceutical and biotechnology companies and research institutes.

Regional Analysis

The Global Primary Cells Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global primary cells market. The market growth in this region is attributed to the presence of a well-established healthcare system, increasing prevalence of cancer, growing government funding in research, and technological advancements. According to the National Cancer Institute, around 1,685,210 new cases of cancer were diagnosed in the US in 2016. A huge patient pool with cancer is thus driving the growth of the market. Increasing healthcare expenditure by government organizations to provide a better life to the people drives the market growth. For instance, in 2017, the healthcare expenditure in the US was USD 3.5 trillion, and this expenditure increased to USD 3.65 Trillion in 2018.

Europe is expected to account for the second-largest market share during the forecast period. The European market is segmented into Germany, the UK, Italy, Spain, France, and the rest of Europe. Europe held a healthy share in the global primary cells market and is the second-largest market leader after the Americas, owing to the presence of favorable government initiatives & laws, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. According to the Office for National Statistics, the gross domestic expenditure on research and development (R&D) activities was EUR 33.1 billion (USD 35.2 billion) in 2016. The increased spending on research and development activity boosts the market growth in this region.

Asia-Pacific is projected to exhibit the fastest market growth from 2019 to 2025 owing to the increasing per capita health spending, growing geriatric population base, and developing the healthcare sector in China, Japan, India, and Australia. According to the World Bank, the healthcare expenditure in India for the year 2016 was 3.66.% of the total GDP (gross domestic product).

The market in the Middle East and Africa is expected to hold the least market share owing to limited access to treatment facilities. However, the increasing invests by healthcare companies in countries such as Saudi Arabia and the launch of new products will help to strengthen the market growth.

Key Players

The Prominent Players in the Global Primary Cells Market are AllCells (US), American Type Culture Collection (ATCC) ( Virginia), Axol Bioscience Ltd (UK), Cell Biologics, Inc. (Chicago), Lonza Group, AG (Switzerland), Merck KGaA (Germany), PromoCell (UK), STEMCELL Technologies Inc. (Canada), ZenBio, Inc. (Research Triangle Park, NC), Thermo Fisher Scientific Inc. (US), and among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/primary-cells-market-6296

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Microtome Market to Witness Steady Growth through 2027

Market Highlights

Microtome Market accounted for USD 120 Million in 2018 at a CAGR of 6.1%.

Market Synopsis

A microtome is a tool used to cut extremely thin sections of tissue samples of plants or animals. Microtomes help in extremely fine cuts that are important for preparations used in microscopy. The high preference of microtome in cancer biopsy will drive the growth positively over the forecast period due to rising cases of cancer worldwide. According to WHO, around 18.1 million new cases of cancer were diagnosed in 2018.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8568

The growth of the upcoming global microtome market trends is driven by various factors such as an increase in the incidence of chronic disorders, increasing prevalence of lifestyle diseases, and increasing mergers & acquisitions by prominent players in the market. However, lack of skilled workforce is projected to hamper the growth of the global microtome market.

The global microtome market is currently dominated by several market players such as Danaher Corporation, Thermo Fisher Scientific, and Sakura Finetek, among others. Additionally, growing growth strategies adopted by market players are driving the growth of the market. For instance, in 2018, Sakura Finetek launched Accu-Cut SRM 300 LT, manual microtome.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising per capita healthcare expenditure. The microtome market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European microtome market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The microtome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of chronic disorders and increasing patient pool, the market in Asia-Pacific is expected to be the fastest-growing. The microtome market in the Middle East & Africa has been bifurcated into the Middle East and Africa.

Segmentation

The Global Microtome Market has been segmented based on product, application, technology, and end-user.

The market, based on product, has been divided into instruments and accessories. Instruments are further sub-segmented into rotary microtomes, cryostat microtomes, vibrating microtomes, and others. Instruments are expected to hold the largest share, due to the commercial availability of these systems and their high adoption rate due to ease of handling.

In terms of application, the global microtome market has been segmented into disease diagnosis and medical research. Disease diagnosis takes up the largest share due to the increasing number of tissue examinations in research laboratories and hospitals owing to rising awareness about the benefits of early diagnosis of diseases like cancer.

In terms of technology, the global microtome market has been segmented into manual, semi-automated microtomes, and fully automated microtomes. The fully automated segment held the majority share due to rising demand for technologically advanced products and its ability to show the highest precision in section thickness. Additionally, fully automated microtomes do not require tedious manual adjustments.

In terms of end-user, the global microtome market has been segmented into hospital laboratories and clinical laboratories. Hospital laboratories take up the largest share. The positive growth of hospitals is attributed to factors such as a high volume of routine tissue examinations performed in hospital-based laboratories across the globe and growing patient population.

Key Players

Some of the key players in the Global Microtome Market are Amos Scientific Pty Ltd (Australia), Danaher (US), Diapath S.p.A. (Italy), Histo-Line Laboratories (Italy), Jinhua YIDI Medical Appliance Co., Ltd (China), MEDITE GmbH (Germany), Boeckeler Instruments, Inc. (US), Sakura Finetek (Japan), SLEE Medical GmbH (Germany), and Thermo Fisher Scientific (US)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microtome-market-8568

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Transarterial Chemoembolization (TACE) Market Industry Production and Demand, Competition News and Trends Forecasts to 2027

Market Forecast

Transarterial Chemoembolization (TACE) Market is expected to cross USD 2777.22 Million by 2025 at a CAGR of 8.57%.

The increasing prevalence of liver cancer is expected to drive the growth of the global transarterial chemoembolization (TACE) market. Hepatocellular carcinoma (HCC) is fifth cancer in terms of incidence and the second leading cause of cancer death for men worldwide. The incidence of HCC is highest in Asia and Africa.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8564

Improvement in the reimbursement scenario is impacting the growth of the market. The cost of sorafenib is reimbursed by Taiwan’s National Health Insurance (NHI) administration with the TACE procedure. Moreover, Lipiodol is approved for National Health Insurance reimbursement for transcatheter arterial chemoembolization for HCC.

Segmentation

By Procedure Type

Conventional TACE: Conventional TACE dominated the Transarterial chemoembolization (TACE) market as it is one of the oldest procedures used in HCC cases. Conventional TACE involves the infusion of chemotherapeutic drugs blended with lipiodol and embolic agents into the cancer-feeding artery

DEB-TACE: This segment is expected to witness the fastest growth. DEB-TACE allows higher concentrations of drugs to the target tumor and lower systemic concentrations, compared with conventional TACE

By Indication

Unresectable HCC: TACE is a major treatment modality for unresectable HCC. The liver tumor which is not eligible for resection therapy given the extent of disease is considered as unresectable HCC

Early-Stage HCC: In case of early-stage HCC, TACE is recommended if resection or local ablation is not feasible

By Product Type

Chemotherapeutic Agents: Held the largest Transarterial Chemoembolization (TACE) Market share in 2018. Doxorubicin, cisplatin, and mitomycin are most commonly used in the TACE procedure. Doxorubicin is the most widely used chemotherapeutic agent for TACE of HCC. The dose of doxorubicin generally ranges from 30 to 75 mg/m2

Radiotherapeutic Agents: TACE with radiotherapeutic agents is the most expensive treatment for liver tumors.

Drug-eluting Particles: Drug-eluting beads have been imposed as novel drug-delivering agents for TACE. DC Beads is one of the most commonly used Drug-eluting beads. These beads are nonbiodegradable PVA microspheres, loaded with calibrated doxorubicin

By End-User

Hospitals & Clinics: It holds the largest market share that can be attributed to an increase in the number of patients afflicted by HCC, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.

Cancer Research Centers: This is the fastest-growing segment due to increasing research funding for the development of effective treatment of HCC

By Region

Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

Europe: The European transarterial chemoembolization (TACE) market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific transarterial chemoembolization (TACE) market is projected to be the fastest-growing during the forecast period.

Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/transarterial-chemoembolization-market-8564

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com